[go: up one dir, main page]

AR029368A1 - A PHARMACEUTICAL COMPOSITION TO TREAT DISEASES MEDIATED BY A CHEMIOQUINE AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS ANTAGONIST OF IL-8 RECEPTORS - Google Patents

A PHARMACEUTICAL COMPOSITION TO TREAT DISEASES MEDIATED BY A CHEMIOQUINE AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS ANTAGONIST OF IL-8 RECEPTORS

Info

Publication number
AR029368A1
AR029368A1 ARP000102925A ARP000102925A AR029368A1 AR 029368 A1 AR029368 A1 AR 029368A1 AR P000102925 A ARP000102925 A AR P000102925A AR P000102925 A ARP000102925 A AR P000102925A AR 029368 A1 AR029368 A1 AR 029368A1
Authority
AR
Argentina
Prior art keywords
manufacture
chemioquine
antagonist
receptors
pharmaceutical composition
Prior art date
Application number
ARP000102925A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR029368A1 publication Critical patent/AR029368A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se refiere a una composicion para el tratamiento de una enfermedad mediada por una quimioquina, seleccionada del grupo constituido por malaria, restenosis, angiogénesis, aterosclerosis, osteoporosis, gingivitis, liberacion hematopoyética indeseada de células madre, y enfermedades causadas por virus respiratorios, herpesvirus, y virus de la hepatitis incluyendo, pero sin limitarse a ellos, el virus de la hepatitis B y hepatitis C, donde la quimioquina se une a un receptor alfa o beta de la IL-8 en un mamífero, que comprende una cantidad efectiva de un compuesto de la formula (1) donde W, W1, Z, R13, R14, y v tienen sus significados dados en la memoria descriptiva y a su uso para la manufactura de un medicamento en el tratamiento de enfermedades mediadas por la quimioquina interleuquina-8 (IL-8).It refers to a composition for the treatment of a chemokine-mediated disease, selected from the group consisting of malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis, unwanted hematopoietic release of stem cells, and diseases caused by respiratory viruses, herpesviruses, and hepatitis virus including, but not limited to, hepatitis B virus and hepatitis C, where chemokine binds to an alpha or beta receptor of IL-8 in a mammal, which comprises an effective amount of a compound of the formula (1) where W, W1, Z, R13, R14, and v have their meanings given in the specification and their use for the manufacture of a medicament in the treatment of diseases mediated by interleukin-8 chemokine (IL- 8).

ARP000102925A 1999-06-16 2000-06-14 A PHARMACEUTICAL COMPOSITION TO TREAT DISEASES MEDIATED BY A CHEMIOQUINE AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS ANTAGONIST OF IL-8 RECEPTORS AR029368A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13967499P 1999-06-16 1999-06-16

Publications (1)

Publication Number Publication Date
AR029368A1 true AR029368A1 (en) 2003-06-25

Family

ID=22487784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102925A AR029368A1 (en) 1999-06-16 2000-06-14 A PHARMACEUTICAL COMPOSITION TO TREAT DISEASES MEDIATED BY A CHEMIOQUINE AND ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS ANTAGONIST OF IL-8 RECEPTORS

Country Status (22)

Country Link
EP (1) EP1191934A4 (en)
JP (1) JP2003501471A (en)
KR (1) KR20020009635A (en)
CN (1) CN1494424A (en)
AR (1) AR029368A1 (en)
AU (1) AU766086B2 (en)
BR (1) BR0010985A (en)
CA (1) CA2377397A1 (en)
CZ (1) CZ20014490A3 (en)
EC (2) ECSP003525A (en)
HK (1) HK1044716A1 (en)
HU (1) HUP0202019A3 (en)
IL (1) IL146214A0 (en)
MX (1) MXPA01013287A (en)
NO (1) NO20016065L (en)
NZ (1) NZ515232A (en)
PE (1) PE20010319A1 (en)
PL (1) PL352218A1 (en)
TR (1) TR200103690T2 (en)
UY (1) UY26209A1 (en)
WO (1) WO2000076516A1 (en)
ZA (1) ZA200110203B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642215B2 (en) * 2001-05-24 2003-11-04 Leo Pharma A/S Method of modulating NF-kB activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2060682T3 (en) * 1988-03-30 1994-12-01 Warner Lambert Co N - ((FENIL (2,6-DISUBSTITUTED)) - N'-ARIL) UREAS AS ANTI-HYPERCHOLESTEROLEMIC AND ANTIATHEROSCLEROTIC AGENTS.
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (en) * 1996-08-15 1999-12-29 Smithkline Beecham Corp NEW COMPOUNDS CONTAINING GUANIDINE USEFUL AS ANTAGONISTS OF IL-8 RECEPTORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE FOR THE PREPARATION OF INTERMEDIARIES.

Also Published As

Publication number Publication date
HUP0202019A3 (en) 2003-03-28
CZ20014490A3 (en) 2002-07-17
PE20010319A1 (en) 2001-05-24
UY26209A1 (en) 2000-12-29
JP2003501471A (en) 2003-01-14
HK1044716A1 (en) 2002-11-01
HUP0202019A2 (en) 2002-10-28
ECSP003525A (en) 2002-01-25
CA2377397A1 (en) 2000-12-21
ZA200110203B (en) 2002-09-11
EP1191934A4 (en) 2004-02-04
KR20020009635A (en) 2002-02-01
IL146214A0 (en) 2002-07-25
AU5748200A (en) 2001-01-02
NO20016065D0 (en) 2001-12-12
MXPA01013287A (en) 2002-06-04
AU766086B2 (en) 2003-10-09
WO2000076516A1 (en) 2000-12-21
PL352218A1 (en) 2003-08-11
ECSP003528A (en) 2002-01-25
NO20016065L (en) 2001-12-12
BR0010985A (en) 2002-03-26
TR200103690T2 (en) 2002-05-21
EP1191934A1 (en) 2002-04-03
NZ515232A (en) 2004-02-27
CN1494424A (en) 2004-05-05

Similar Documents

Publication Publication Date Title
MA28011A1 (en) PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
ES2178430T3 (en) USE OF GELIFICABLE PHARMACEUTICAL COMPOSITIONS IN PARODONTOLOGY.
CO5310576A1 (en) HETEROCICLING COMPOUNDS LIKE GABAA RECEIVERS
BR0108600A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and methods for treating a chemokine-mediated disease and for treating an inflammatory disease
UY27466A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS WITH 4'-NUCLEOSID MODIFICATIONS
ECSP055935A (en) MEDICATION FOR PROPHYLAXIS AND TREATMENT OF ARTERIOSCLEROSIS AND HYPERTENSION
PT1119543E (en) N-ARALHYLAMINOTETRALINES AS LIGANDS FOR NEUROPEPTIDE AND Y5 RECEPTOR
AR029222A1 (en) COMPOUND DERIVED FROM AMIDA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF MEDICINES TO TREAT DISEASES MEDIATED BY PROTEINQUINASE
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
BRPI0710232B8 (en) IL-8 receptor antagonist compound, pharmaceutical composition comprising said compound and use thereof for the treatment of a chemokine-mediated disease
UY28084A1 (en) NUCLEOSID ANTIVIRAL DERIVATIVES
NO20083585L (en) Hetero-cyclic antiviral compounds
ECSP066312A (en) PIRIDILO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
ES2177346T3 (en) SLOW RELEASE RANOLAZINE FORMULATIONS.
BR0210322A (en) Pearly Cleansing Makeup for Personal Care
AR030391A1 (en) COMPOSITION TO TREAT A STATE OF DISEASE MEDIATED BY CHEMIOQUINS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
BRPI0514661B8 (en) vasopressin v1a antagonists, pharmaceutical composition and use of said antagonists
PL1716152T3 (en) Condensed heterocycles and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
BRPI0408362A (en) combination of an aldosterone receptor antagonist and an antidiabetic agent
WO2001023357A3 (en) Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists
AR039190A1 (en) BENZOFURAN DERIVATIVES, PHARMACEUTICAL COMPOSITION AND MEDICINAL PRODUCT UNDERSTANDING THE COMPOUND
BRPI0519398A2 (en) Pyridine Compounds for the Treatment of Prostaglandin-Mediated Diseases
DE60215313D1 (en) INDOIND DERIVATIVES AND THEIR USE AS GNRH ANTAGONISTS
PE20011004A1 (en) CONTROLLED RELEASE COMPOSITION OF A PHOSPHODIESTERASE 4 INHIBITOR

Legal Events

Date Code Title Description
FA Abandonment or withdrawal